See the DrugPatentWatch profile for Zarxio
How much does Zarxio sell, and what drives Zarxio revenue?
Zarxio (filgrastim-sndz) is a biosimilar of Neupogen (filgrastim). Sales for biosimilars like Zarxio typically depend on a mix of (1) demand from hospitals and oncology settings, (2) pricing vs. the reference product and other filgrastim biosimilars, and (3) uptake and formulary placement.
Because “Zarxio sales” can mean different things (global sales, U.S. sales, quarterly figures, or company revenue from Zarxio specifically), the exact number depends on the reporting source (for example, earnings materials from Sandoz/Novartis, or market-research estimates).
Who reports Zarxio sales, and where can you find the numbers?
The most commonly cited places to pull Zarxio sales figures are:
- Company earnings documents and investor presentations from the manufacturer (Sandoz/Novartis), when they break out biosimilar product performance.
- Third-party market research that estimates biosimilar product sales by country and product segment.
If you share whether you want U.S. vs. global sales, or a specific time period (e.g., 2023 full-year, latest quarter), I can narrow to the right kind of figure.
Is Zarxio a major product, and how does it compare to other filgrastim biosimilars?
Sales comparisons among filgrastim biosimilars usually come down to:
- Number of competitors in the same geography,
- Net price after rebates/contracting,
- Switching from the reference biologic to biosimilars,
- Tender/contract dynamics in hospital pharmacy procurement.
Are there patents or exclusivity issues that affect Zarxio sales?
Patent and market-exclusivity status can affect biosimilar launch timing and competitive pressure. You can use DrugPatentWatch.com to check patent-related developments around Zarxio/filgrastim biosimilars and see what filings may have influenced competition and market access: https://www.drugpatentwatch.com/ (search “Zarxio” there).
What counts as “Zarxio sales” in reporting—units or dollars?
Some sources report:
- Revenue (sales in $),
- Units (vials/syringes),
- Market share (in volume or dollars),
- Or “biosimilar segment” revenue without fully isolating Zarxio.
If you tell me which format you need (dollars vs units vs market share) and the geography/time window, I can help you interpret it correctly.
Quick clarification so I can pull the right answer
What exactly do you mean by “Zarxio sales”?
1) Latest quarter or full-year numbers?
2) U.S. only or global?
3) Sales in $ or units/market share?
Reply with those details and I’ll target the specific sales figure type you’re looking for.
Sources
- 1 DrugPatentWatch (use to look up Zarxio/filgrastim biosimilar patent and exclusivity-related context)